{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T18:18:08Z","timestamp":1790965088801,"version":"4.1.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1038\/s41401-025-01681-w","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T06:44:08Z","timestamp":1762152248000},"page":"1015-1028","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["MS1-96 induces HIP1R-dependent PD-L1 degradation and promotes antitumor immunity in colorectal cancer"],"prefix":"10.1038","volume":"47","author":[{"given":"Jin-jin","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-yi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-tian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing-xin","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-shuang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-qing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Di","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Han","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-dao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-jun","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"1681_CR1","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrc.2016.36","volume":"16","author":"SL Topalian","year":"2016","unstructured":"Topalian SL, Taube JM, Anders RA, Pardoll DM. Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy. Nat Rev Cancer. 2016;16:275\u201387.","journal-title":"Nat Rev Cancer"},{"key":"1681_CR2","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","volume":"12","author":"DM Pardoll","year":"2012","unstructured":"Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252\u201364.","journal-title":"Nat Rev Cancer"},{"key":"1681_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"key":"1681_CR4","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.canlet.2013.03.010","volume":"336","author":"Y Ge","year":"2013","unstructured":"Ge Y, Xi H, Ju S, Zhang X. Blockade of PD-1\/PD-L1 immune checkpoint during DC vaccination induces potent protective immunity against breast cancer in hu-SCID mice. Cancer Lett. 2013;336:253\u20139.","journal-title":"Cancer Lett"},{"key":"1681_CR5","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J"},{"key":"1681_CR6","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","volume":"48","author":"C Sun","year":"2018","unstructured":"Sun C, Mezzadra R, Schumacher TN. Regulation and function of the PD-L1 checkpoint. Immunity. 2018;48:434\u201352.","journal-title":"Immunity"},{"key":"1681_CR7","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","volume":"76","author":"JH Cha","year":"2019","unstructured":"Cha JH, Chan LC, Li CW, Hsu JL, Hung MC. Mechanisms controlling PD-L1 expression in cancer. Mol Cell. 2019;76:359\u201370.","journal-title":"Mol Cell"},{"key":"1681_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-024-02023-w","volume":"23","author":"X Lin","year":"2024","unstructured":"Lin X, Kang K, Chen P, Zeng Z, Li G, Xiong W, et al. Regulatory mechanisms of PD-1\/PD-L1 in cancers. Mol Cancer. 2024;23:108.","journal-title":"Mol Cancer"},{"key":"1681_CR9","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027\u201334.","journal-title":"J Exp Med"},{"key":"1681_CR10","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793\u2013800.","journal-title":"Nat Med"},{"key":"1681_CR11","doi-asserted-by":"publisher","first-page":"F459","DOI":"10.1152\/ajprenal.90340.2008","volume":"296","author":"O Vagin","year":"2009","unstructured":"Vagin O, Kraut JA, Sachs G. Role of N-glycosylation in trafficking of apical membrane proteins in epithelia. Am J Physiol Ren Physiol. 2009;296:F459\u201369.","journal-title":"Am J Physiol Ren Physiol"},{"key":"1681_CR12","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12632","volume":"7","author":"CW Li","year":"2016","unstructured":"Li CW, Lim SO, Xia W, Lee HH, Chan LC, Kuo CW, et al. Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. Nat Commun. 2016;7:12632.","journal-title":"Nat Commun"},{"key":"1681_CR13","doi-asserted-by":"publisher","first-page":"544","DOI":"10.3390\/cells8060544","volume":"8","author":"KB Chandler","year":"2019","unstructured":"Chandler KB, Costello CE, Rahimi N. Glycosylation in the tumor microenvironment: implications for tumor angiogenesis and metastasis. Cells. 2019;8:544.","journal-title":"Cells"},{"key":"1681_CR14","doi-asserted-by":"publisher","first-page":"2120","DOI":"10.3389\/fimmu.2019.02120","volume":"10","author":"H L\u00e4ubli","year":"2019","unstructured":"L\u00e4ubli H, Borsig L. Altered cell adhesion and glycosylation promote cancer immune suppression and metastasis. Front Immunol. 2019;10:2120.","journal-title":"Front Immunol"},{"key":"1681_CR15","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.3390\/biomedicines9111702","volume":"9","author":"X Yu","year":"2021","unstructured":"Yu X, Li W, Young KH, Li Y. Posttranslational modifications in PD-L1 turnover and function: from cradle to grave. Biomedicines. 2021;9:1702.","journal-title":"Biomedicines"},{"key":"1681_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.ccell.2018.01.009","volume":"33","author":"CW Li","year":"2018","unstructured":"Li CW, Lim SO, Chung EM, Kim YS, Park AH, Yao J, et al. Eradication of triple-negative breast cancer cells by targeting glycosylated PD-L1. Cancer Cell. 2018;33:187\u2013201.e10.","journal-title":"Cancer Cell"},{"key":"1681_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1038\/nrm4073","volume":"16","author":"C Xu","year":"2015","unstructured":"Xu C, Ng DT. Glycosylation-directed quality control of protein folding. Nat Rev Mol Cell Biol. 2015;16:742\u201352.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1681_CR18","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","volume":"379","author":"P Schmid","year":"2018","unstructured":"Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108\u201321.","journal-title":"N Engl J Med"},{"key":"1681_CR19","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/S1470-2045(22)00226-1","volume":"23","author":"BC Cho","year":"2022","unstructured":"Cho BC, Abreu DR, Hussein M, Cobo M, Patel AJ, Secen N, et al. Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. Lancet Oncol. 2022;23:781\u201392.","journal-title":"Lancet Oncol"},{"key":"1681_CR20","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919\u201329.","journal-title":"N Engl J Med"},{"key":"1681_CR21","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","volume":"383","author":"T Powles","year":"2020","unstructured":"Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med. 2020;383:1218\u201330.","journal-title":"N Engl J Med"},{"key":"1681_CR22","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1200\/JCO.23.01891","volume":"42","author":"S Park","year":"2024","unstructured":"Park S, Kim TM, Han JY, Lee GW, Shim BY, Lee YG, et al. Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04). J Clin Oncol. 2024;42:1241\u201351.","journal-title":"J Clin Oncol"},{"key":"1681_CR23","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375\u201391.","journal-title":"Ann Oncol"},{"key":"1681_CR24","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2016.04.011","volume":"21","author":"MM Zhan","year":"2016","unstructured":"Zhan MM, Hu XQ, Liu XX, Ruan BF, Xu J, Liao C. From monoclonal antibodies to small molecules: the development of inhibitors targeting the PD-1\/PD-L1 pathway. Drug Discov Today. 2016;21:1027\u201336.","journal-title":"Drug Discov Today"},{"key":"1681_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2020.112377","volume":"199","author":"B Cheng","year":"2020","unstructured":"Cheng B, Ren Y, Cao H, Chen J. Discovery of novel resorcinol diphenyl ether-based PROTAC-like molecules as dual inhibitors and degraders of PD-L1. Eur J Med Chem. 2020;199:112377.","journal-title":"Eur J Med Chem"},{"key":"1681_CR26","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","volume":"584","author":"SM Banik","year":"2020","unstructured":"Banik SM, Pedram K, Wisnovsky S, Ahn G, Riley NM, Bertozzi CR. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584:291\u20137.","journal-title":"Nature"},{"key":"1681_CR27","doi-asserted-by":"publisher","first-page":"16377","DOI":"10.1021\/jacs.1c08521","volume":"143","author":"H Zhang","year":"2021","unstructured":"Zhang H, Han Y, Yang Y, Lin F, Li K, Kong L, et al. Covalently engineered nanobody chimeras for targeted membrane protein degradation. J Am Chem Soc. 2021;143:16377\u201382.","journal-title":"J Am Chem Soc"},{"key":"1681_CR28","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/s41587-022-01456-2","volume":"41","author":"K Pance","year":"2023","unstructured":"Pance K, Gramespacher JA, Byrnes JR, Salangsang F, Serrano JC, Cotton AD, et al. Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins. Nat Biotechnol. 2023;41:273\u201381.","journal-title":"Nat Biotechnol"},{"key":"1681_CR29","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41589-018-0161-x","volume":"15","author":"H Wang","year":"2019","unstructured":"Wang H, Yao H, Li C, Shi H, Lan J, Li Z, et al. HIP1R targets PD-L1 to lysosomal degradation to alter T cell-mediated cytotoxicity. Nat Chem Biol. 2019;15:42\u201350.","journal-title":"Nat Chem Biol"},{"key":"1681_CR30","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1021\/acsptsci.2c00089","volume":"5","author":"C Zhao","year":"2022","unstructured":"Zhao C, Dekker FJ. Novel design strategies to enhance the efficiency of proteolysis targeting chimeras. ACS Pharm Transl Sci. 2022;5:710\u201323.","journal-title":"ACS Pharm Transl Sci"},{"key":"1681_CR31","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1831153","volume":"9","author":"FF Chen","year":"2020","unstructured":"Chen FF, Li Z, Ma D, Yu Q. Small-molecule PD-L1 inhibitor BMS1166 abrogates the function of PD-L1 by blocking its ER export. Oncoimmunology. 2020;9:1831153.","journal-title":"Oncoimmunology"},{"key":"1681_CR32","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/j.molcel.2018.07.030","volume":"71","author":"JH Cha","year":"2018","unstructured":"Cha JH, Yang WH, Xia W, Wei Y, Chan LC, Lim SO, et al. Metformin promotes antitumor immunity via endoplasmic-reticulum-associated degradation of PD-L1. Mol Cell. 2018;71:606\u201320.e7.","journal-title":"Mol Cell"},{"key":"1681_CR33","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1091\/mbc.e04-08-0740","volume":"16","author":"Y Sun","year":"2005","unstructured":"Sun Y, Kaksonen M, Madden DT, Schekman R, Drubin DG. Interaction of Sla2p\u2019s ANTH domain with PtdIns(4,5)P2 is important for actin-dependent endocytic internalization. Mol Biol Cell. 2005;16:717\u201330.","journal-title":"Mol Biol Cell"},{"key":"1681_CR34","doi-asserted-by":"publisher","first-page":"E2533","DOI":"10.1073\/pnas.1207011109","volume":"109","author":"M Skruzny","year":"2012","unstructured":"Skruzny M, Brach T, Ciuffa R, Rybina S, Wachsmuth M, Kaksonen M. Molecular basis for coupling the plasma membrane to the actin cytoskeleton during clathrin-mediated endocytosis. Proc Natl Acad Sci USA. 2012;109:E2533\u201342.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1681_CR35","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1146\/annurev.cellbio.19.111401.093127","volume":"19","author":"AE Engqvist-Goldstein","year":"2003","unstructured":"Engqvist-Goldstein AE, Drubin DG. Actin assembly and endocytosis: from yeast to mammals. Annu Rev Cell Dev Biol. 2003;19:287\u2013332.","journal-title":"Annu Rev Cell Dev Biol"},{"key":"1681_CR36","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/S0955-0674(01)00297-6","volume":"14","author":"DA Schafer","year":"2002","unstructured":"Schafer DA. Coupling actin dynamics and membrane dynamics during endocytosis. Curr Opin Cell Biol. 2002;14:76\u201381.","journal-title":"Curr Opin Cell Biol"},{"key":"1681_CR37","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1083\/jcb.200403120","volume":"165","author":"S Carreno","year":"2004","unstructured":"Carreno S, Engqvist-Goldstein AE, Zhang CX, McDonald KL, Drubin DG. Actin dynamics coupled to clathrin-coated vesicle formation at the trans-Golgi network. J Cell Biol. 2004;165:781\u20138.","journal-title":"J Cell Biol"},{"key":"1681_CR38","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1083\/jcb.147.7.1503","volume":"147","author":"AE Engqvist-Goldstein","year":"1999","unstructured":"Engqvist-Goldstein AE, Kessels MM, Chopra VS, Hayden MR, Drubin DG. An actin-binding protein of the Sla2\/Huntingtin interacting protein 1 family is a novel component of clathrin-coated pits and vesicles. J Cell Biol. 1999;147:1503\u201318.","journal-title":"J Cell Biol"},{"key":"1681_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101357","volume":"5","author":"Q Wang","year":"2024","unstructured":"Wang Q, Wang J, Yu D, Zhang Q, Hu H, Xu M, et al. Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3. Cell Rep Med. 2024;5:101357.","journal-title":"Cell Rep Med"},{"key":"1681_CR40","doi-asserted-by":"publisher","first-page":"8509","DOI":"10.1002\/jcp.27782","volume":"234","author":"B Farhood","year":"2019","unstructured":"Farhood B, Najafi M, Mortezaee K. CD8\u207a cytotoxic T lymphocytes in cancer immunotherapy: A review. J Cell Physiol. 2019;234:8509\u201321.","journal-title":"J Cell Physiol"},{"key":"1681_CR41","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/nri1349","volume":"4","author":"L Chen","year":"2004","unstructured":"Chen L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. Nat Rev Immunol. 2004;4:336\u201347.","journal-title":"Nat Rev Immunol"},{"key":"1681_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-022-00854-y","volume":"20","author":"A Naimi","year":"2022","unstructured":"Naimi A, Mohammed RN, Raji A, Chupradit S, Yumashev AV, Suksatan W, et al. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons. Cell Commun Signal. 2022;20:44.","journal-title":"Cell Commun Signal"},{"key":"1681_CR43","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1146\/annurev-biochem-061516-044859","volume":"86","author":"A Varshavsky","year":"2017","unstructured":"Varshavsky A. The ubiquitin system, autophagy, and regulated protein degradation. Annu Rev Biochem. 2017;86:123\u20138.","journal-title":"Annu Rev Biochem"},{"key":"1681_CR44","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114851119","volume":"119","author":"R Zhang","year":"2022","unstructured":"Zhang R, Yang Y, Dong W, Lin M, He J, Zhang X, et al. D-mannose facilitates immunotherapy and radiotherapy of triple-negative breast cancer via degradation of PD-L1. Proc Natl Acad Sci USA. 2022;119:e2114851119.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1681_CR45","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nature23643","volume":"549","author":"ML Burr","year":"2017","unstructured":"Burr ML, Sparbier CE, Chan YC, Williamson JC, Woods K, Beavis PA, et al. CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity. Nature. 2017;549:101\u20135.","journal-title":"Nature"},{"key":"1681_CR46","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1080\/15548627.2024.2439657","volume":"21","author":"B Hao","year":"2025","unstructured":"Hao B, Lin S, Liu H, Xu J, Chen L, Zheng T, et al. Baicalein tethers CD274\/PD-L1 for autophagic degradation to boost antitumor immunity. Autophagy. 2025;21:917\u201333.","journal-title":"Autophagy"},{"key":"1681_CR47","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383:2207\u201318.","journal-title":"N Engl J Med"},{"key":"1681_CR48","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1200\/JCO.19.02107","volume":"38","author":"DT Le","year":"2020","unstructured":"Le DT, Kim TW, Van Cutsem E, Geva R, J\u00e4ger D, Hara H, et al. Phase II open-label study of pembrolizumab in treatment-refractory, microsatellite instability-high\/mismatch repair-deficient metastatic colorectal cancer: KEYNOTE-164. J Clin Oncol. 2020;38:11\u20139.","journal-title":"J Clin Oncol"},{"key":"1681_CR49","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1126\/science.aan6733","volume":"357","author":"DT Le","year":"2017","unstructured":"Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357:409\u201313.","journal-title":"Science"},{"key":"1681_CR50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ebiom.2019.01.054","volume":"40","author":"N Zhang","year":"2019","unstructured":"Zhang N, Dou Y, Liu L, Zhang X, Liu X, Zeng Q, et al. SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1. EBioMedicine. 2019;40:151\u201362.","journal-title":"EBioMedicine"},{"key":"1681_CR51","doi-asserted-by":"publisher","first-page":"8256","DOI":"10.1073\/pnas.0801340105","volume":"105","author":"D Shental-Bechor","year":"2008","unstructured":"Shental-Bechor D, Levy Y. Effect of glycosylation on protein folding: a close look at thermodynamic stabilization. Proc Natl Acad Sci USA. 2008;105:8256\u201361.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1681_CR52","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12929-020-00670-x","volume":"27","author":"YN Wang","year":"2020","unstructured":"Wang YN, Lee HH, Hsu JL, Yu D, Hung MC. The impact of PD-L1\u2009N-linked glycosylation on cancer therapy and clinical diagnosis. J Biomed Sci. 2020;27:77.","journal-title":"J Biomed Sci"},{"key":"1681_CR53","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.72583","volume":"10","author":"N Pashkova","year":"2021","unstructured":"Pashkova N, Gakhar L, Yu L, Schnicker NJ, Minard AY, Winistorfer S, et al. ANTH domains within CALM, HIP1R, and Sla2 recognize ubiquitin internalization signals. Elife. 2021;10:e72583.","journal-title":"Elife"},{"key":"1681_CR54","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/sj.emboj.7601576","volume":"26","author":"C Le Clainche","year":"2007","unstructured":"Le Clainche C, Pauly BS, Zhang CX, Engqvist-Goldstein AE, Cunningham K, Drubin DG. A Hip1R-cortactin complex negatively regulates actin assembly associated with endocytosis. EMBO J. 2007;26:1199\u2013210.","journal-title":"EMBO J"},{"key":"1681_CR55","doi-asserted-by":"publisher","first-page":"6349","DOI":"10.1158\/0008-5472.CAN-18-1892","volume":"78","author":"JM Hsu","year":"2018","unstructured":"Hsu JM, Li CW, Lai YJ, Hung MC. Posttranslational modifications of PD-L1 and their applications in cancer therapy. Cancer Res. 2018;78:6349\u201353.","journal-title":"Cancer Res"},{"key":"1681_CR56","first-page":"1837","volume":"8","author":"B Shao","year":"2018","unstructured":"Shao B, Li CW, Lim SO, Sun L, Lai YJ, Hou J, et al. Deglycosylation of PD-L1 by 2-deoxyglucose reverses PARP inhibitor-induced immunosuppression in triple-negative breast cancer. Am J Cancer Res. 2018;8:1837\u201346.","journal-title":"Am J Cancer Res"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01681-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01681-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T23:02:09Z","timestamp":1774479729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01681-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":56,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["1681"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01681-w","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"21 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}